Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2018

View Archived Issues

CYT-21625 shows promising activity in models of thyroid and pancreatic neuroendocrine tumors

The flavonoid fisetin inhibits senescence and reduces age-related pathologies in elderly mice

HPV vaccination increases efficacy of PD-1 checkpoint inhibition in incurable HPV 16-related cancer

Phase I results on the combination valproate/rituximab/CHOP in diffuse large B-cell lymphoma

Safety and preliminary efficacy data from phase II study of atezolizumab plus CRT in NSCLC

The pot scrubbing the kettle: Malaria parasites could combat chikungunya symptoms

Cyclacel Pharmaceuticals forms alliance with MD Anderson Cancer Center

Patient recruitment ongoing in phase I/II study of imaging agent 89Zr-DFO-daratumumab

KINGS mouse as a novel preclinical model of diabetes

Hepato-preferential insulin analogue protects dogs from hypoglycemia

Bristol-Myers Squibb enrolling participants in phase I/II study of BMS-986310

NextCure initiates phase I/II trial of its novel antibody candidate, NC-318

First phase II results presented for LY-3298176 in patients with type 2 diabetes

Calithera Biosciences enters collaboration with Pfizer for combination studies of CB-839

Progenics reports promising phase II/III data on PyL for detection of prostate cancer

FDA approves Tegsedi to treat polyneuropathy of hATTR in adults

Revcovi approved in U.S. for ADA-SCID

Gardasil 9 approved by FDA for adults aged 27-45 years

4CMenB shows protective antibody titers 7.5 years after vaccination in adolescents and young adults

Discovery of the first nonpeptide OT-R agonist active in a mouse model of autism

UMC Utrecht Holding synthesizes modified serpins for bradykinin-mediated diseases

Two-fisted punch prevents HIV rebound

U.S. researchers divulge bacterial efflux pump inhibitors

Genentech and University of California, Oakland disclose IRE1 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...